Atiprimod (Azaspirane) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2alpha/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-kappaB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML)[1][2][3][4][5][6].
Molecular Weight:
336.60
CAS Number:
[123018-47-3]
Formula:
C22H44N2
Target:
Apoptosis,Atg8/LC3,Autophagy,Bcl-2 Family,Caspase,JAK,NF-kappaB,p62,PARP,PERK,Reactive Oxygen Species (ROS),STAT
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
